PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 100, Issue , 2016, Pages 88-98

  Gandini, Sara ^a   Massi, Daniela ^b   Mandalà, Mario ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Anti PD 1 PD L1 antibodies; Clinical trials; Melanoma; Meta analysis; PD L1 overexpression

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTIBODY; PDCD1 PROTEIN, HUMAN;

CANCER MORTALITY; CANCER PATIENT; CHECKLIST; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; META ANALYSIS; METABOLISM; METASTASIS; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIBODIES; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84960424344     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.02.001     Document Type: Review

References (56)

1. Akbay E.A., Koyama S., Carretero J., Altabef A., Tchaicha J.H., Christensen C.L., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013, 3:1355-1363.
2. Atkinson V., Ascierto P.A., Long G.V., Brady B., Dutriaux C., Maio M., et al., 2015. Two-year Survival and Safety Update in Patients With Treatment-naïve Advanced Melanoma Receiving Nivolumab or Dacarbazine in CheckMate 066, SMR.
3. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 2014, 25:1935-1940.
4. Berry S., Taube J.M. Innate vs: adaptive: pD-L1-mediated immune resistance by melanoma. Oncoimmunology 2015, 4:e1029704.
5. Callea M., Albiges L., Gupta M., Cheng S.C., Genega E.M., Fay A.P., et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 2015, 3:1158-1164.
6. Chen J., Jiang C.C., Jin L., Zhang X.D. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 2015.
7. Choueiri T.K., Fishman M.N. Escudier B., Kim J.J., Kluger H., Stadler H., et al., 2014. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial:ASCO.
8. Clarke M. The QUORUM statement. Lancet 2000, 355:756-757.
9. D'Incecco A., Andreozzi M., Ludovini V., Rossi E., Capodanno A., Landi L., et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br. J. Cancer 2015, 112:95-102.
10. Daud A., Hamid O., Robert C., Hodi F.S., Wolchok J.D., Hwu W.J., et al. Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475). Eur. J. Cancer 2014, 50:48-49.
11. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:2018-2028.
12. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2015, 33:2004-2012.
13. Gibney G.T., Kudchadkar R.R., DeConti R.C., Thebeau M.S., Czupryn M.P., Tetteh L., et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 2015, 21:712-720.
14. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 1987, 9:1-30.
15. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
17. Hodi F.S., Sznol M., Kluger H.M., McDermott D.F., Carvajal R.D., Lawrence D.P., et al., 2014. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial:ASCO.
18. Kohlhapp F.J., Kaufman H.L. Molecular pathways mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 2015.
19. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 2004, 10:5094-5100.
20. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373:23-34.
21. Macaskill P., Walter S.D., Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat. Med. 2001, 20:641-654.
22. Madore J., Vilain R.E., Menzies A.M., Kakavand H., Wilmott J.S., Hyman J., et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigm. Cell Melanoma Res. 2015, 28:245-253.
23. Massi D., Brusa D., Merelli B., Ciano M., Audrito V., Serra S., et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann. Oncol. 2014, 25:2433-2442.
24. Massi D., Brusa D., Merelli B., Falcone C., Xue G., Carobbio A., et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann. Oncol. 2015.
25. McDermott D.F., Drake C.G., Sznol M., Choueiri T.K., Powderly J.D., Smith D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 2015, 33:2013-2020.
26. McLaughlin J., Han G., Schalper K.A., Carvajal-Hausdorf D., Pelakanou V., Rehman J., et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2015, 1-9.
27. Moher D., Schulz K.F., Altman D., CONSORT Group (Consolidated Standards of Reporting Trials) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991.
28. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
29. Paz-Ares L., Horn L., Borghaei H., Spigel D.R., Steins M., Neal E., et al., 2015. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC):ASCO.
30. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 2015, 33:1974-1982.
31. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
32. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015.
33. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
34. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372:2521-2532.
35. Rozali E.N., Hato S.V., Robinson B.W., Lake R.A., Lesterhuis W.J. Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol. 2012, 2012:656340.
36. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194.
37. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next. Curr. Opin. Immunol. 2015, 33:23-35.
38. Spira A.I., Park K., Mazieres J., Vansteenkiste J., Rittmeyer A., Ballinger M., et al., 2015. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR):ASCO.
39. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014, 2(3). (1426-2-3. eCollection 2014).
40. Stuart A.O.K. Kendall's Advanced Theory of Statistics 1994, John Wiley & Sons, Hoboken, NJ, USA. 6th ed.
41. Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clin. Cancer Res. 2013, 19. 5542, 0432, CCR-13-2234, Epub 2013 Sep 18.
42. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4. 127ra37.
43. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20:5064-5074.
44. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
45. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17174-17179.
46. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
47. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
48. Wainwright D.A., Chang A.L., Dey M., Balyasnikova I.V., Kim C.K., Tobias A., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 2014, 20:5290-5301.
49. Wargo J.A., Cooper Z.A., Flaherty K.T. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014, 4:1377-1386.
50. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 2013, 31:4311-4318.
51. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
52. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.-, Cowey C.L., et al., 2015. Efficacy and safety results from a Phase III trial of nivolumab slone or combined with ipilimumab vs. ipilimumab alone in treatment-naïve patients with advanced melanoma (CheckMate 067); Abstract #LBA1:ASCO.
53. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012, 72:917-927.
54. Yoshii A., Plaut D.A., McGraw K.A., Anderson M.J., Wellik K.E. Analysis of the reporting of search strategies in Cochrane systematic reviews. J. Med. Libr. Assoc. 2009, 97:21-29.
55. van Houwelingen H.C., Arends L.R., Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat. Med. 2002, 21:589-624.
56. Puzanov I., Dummer R., Schachter J., Pavlick A.C., Gonzalez Rene Ascierto, Antonio Paolo, et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). J. Clin. Oncol. 2015, 33:3012. ASCO Annual Meeting, 2015.